Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABEO Abeona Therapeutics	$6.12 -4.7%	$5.34	$3.93 ▼ $7.32	$313.08M	1.68	623,569 shs	1.55 million shs
DARE Daré Bioscience	$2.80 -3.4%	$2.91	$2.67 ▼ $6.24	$25.67M	1.2	36,650 shs	129,998 shs
INCR InterCure	$1.55	$1.45	$1.17 ▼ $3.32	$70.64M	1.25	28,737 shs	13,611 shs
TLSA Tiziana Life Sciences	$1.43 -9.5%	$1.21	$0.63 ▼ $1.91	$167.09M	0.29	476,867 shs	426,612 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABEO Abeona Therapeutics	0.00%	+3.05%	+20.45%	+20.45%	+58.13%
DARE Daré Bioscience	0.00%	-0.68%	-2.68%	-7.35%	-44.57%
INCR InterCure	0.00%	-1.90%	+4.73%	-4.91%	-51.10%
TLSA Tiziana Life Sciences	0.00%	+6.76%	+16.18%	+64.58%	+95.09%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABEO Abeona Therapeutics	3.7897 of 5 stars	3.5	1.0	4.5	3.1	2.5	0.0
DARE Daré Bioscience	1.6778 of 5 stars	3.3	3.0	0.0	3.3	0.0	0.0
INCR InterCure	1.1227 of 5 stars	0.0	5.0	0.0	3.3	0.0	0.6
TLSA Tiziana Life Sciences	0.9956 of 5 stars	0.0	5.0	0.0	2.5	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABEO Abeona Therapeutics	3.00	Buy	$18.50	202.29% Upside
DARE Daré Bioscience	2.50	Moderate Buy	$12.00	328.57% Upside
INCR InterCure	0.00	N/A	N/A	N/A
TLSA Tiziana Life Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest ABEO, DARE, TLSA, and INCR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	ABEO Abeona Therapeutics	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$21.00 ➝ $20.00
5/15/2025	ABEO Abeona Therapeutics	Alliance Global Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/30/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $20.00
4/1/2025	DARE Daré Bioscience	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/24/2025	ABEO Abeona Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/5/2025	ABEO Abeona Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$16.00

(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABEO Abeona Therapeutics	$3.50M	89.45	N/A	N/A	$0.60 per share	10.20
DARE Daré Bioscience	$25.91K	956.42	N/A	N/A	($0.61) per share	-4.59
INCR InterCure	$238.85M	0.30	N/A	N/A	$2.72 per share	0.57
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	$0.05 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABEO Abeona Therapeutics	-$54.19M	-$1.27	N/A	N/A	N/A	N/A	-203.27%	-64.56%	8/11/2025 (Estimated)
DARE Daré Bioscience	-$30.16M	-$0.17	N/A	N/A	N/A	-191.65%	N/A	-18.98%	8/11/2025 (Estimated)
INCR InterCure	-$16.83M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	-$17.69M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest ABEO, DARE, TLSA, and INCR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/15/2025	Q1 2025	ABEO Abeona Therapeutics	-$0.35	-$0.24	+$0.11	-$0.24	N/A	N/A
5/13/2025	Q1 2025	DARE Daré Bioscience	-$0.63	-$0.50	+$0.13	-$0.50	$0.60 million	$0.03 million
3/31/2025	Q4 2024	DARE Daré Bioscience	-$0.66	-$0.64	+$0.02	-$0.64	$1.00 million	($0.06) million
3/20/2025	Q4 2024	ABEO Abeona Therapeutics	-$0.43	-$0.24	+$0.19	-$0.14	$0.10 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABEO Abeona Therapeutics	N/A	N/A	N/A	N/A	N/A
DARE Daré Bioscience	N/A	N/A	N/A	N/A	N/A
INCR InterCure	N/A	N/A	N/A	N/A	N/A
TLSA Tiziana Life Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABEO Abeona Therapeutics	0.31	6.12	6.12
DARE Daré Bioscience	N/A	1.14	1.14
INCR InterCure	0.15	1.78	1.15
TLSA Tiziana Life Sciences	N/A	0.85	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABEO Abeona Therapeutics	80.56%
DARE Daré Bioscience	6.70%
INCR InterCure	8.34%
TLSA Tiziana Life Sciences	N/A

Insider Ownership

Company	Insider Ownership
ABEO Abeona Therapeutics	6.90%
DARE Daré Bioscience	4.00%
INCR InterCure	0.24%
TLSA Tiziana Life Sciences	39.82%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABEO Abeona Therapeutics	N/A	51.16 million	41.12 million	Optionable
DARE Daré Bioscience	30	8.85 million	8.35 million	Not Optionable
INCR InterCure	350	45.57 million	45.46 million	Optionable
TLSA Tiziana Life Sciences	8	116.85 million	63.43 million	Optionable

ABEO, DARE, TLSA, and INCR Headlines

Recent News About These Companies

Tiziana Life Sciences (NASDAQ:TLSA) Stock Price Up 15.3% - Here's What Happened

May 27 at 1:37 AM | americanbankingnews.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer’s Disease

May 23, 2025 | finance.yahoo.com

Tiziana Life Sciences Announces Interview Highlighting Intranasal Foralumab for the Treatment of Moderate Alzheimer's Disease

May 23, 2025 | globenewswire.com

Journal of Clinical Nuclear Medicine Publishes Results of Tiziana’s Nasal Foralumab in Study Treating Moderate Alzheimer's Disease

May 15, 2025 | finance.yahoo.com

Tiziana Life Sciences' foralumab reduced neuroinflammation in Alzheimer's patient, study shows

May 15, 2025 | proactiveinvestors.com

Tiziana Life Sciences reports purchase of shares by chairman

May 12, 2025 | msn.com

Tiziana Life Sciences Announces Purchase of Shares by Chairman

May 12, 2025 | globenewswire.com

Tiziana Life Sciences reports reduced brain inflammation in Alzheimer's patient treated with nasal foralumab

May 9, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Significant Reduction in Microglia Activation in PET Scan of Moderate Alzheimer's Patient Treated with Intranasal Foralumab

May 9, 2025 | globenewswire.com

Tiziana Life Sciences’ intranasal MS candidate shows promise in open-label study

May 8, 2025 | pmlive.com

Tiziana shares surge 21% on promising multiple sclerosis data

May 6, 2025 | proactiveinvestors.com

Tiziana reports encouraging results for nasal MS drug in early study

May 6, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Comprehensive Positive Results from Study of Nasal Foralumab in Patients with Multiple Sclerosis

May 6, 2025 | globenewswire.com

Why Tiziana Life Sciences Ltd (TLSA) is Surging in 2025

April 30, 2025 | insidermonkey.com

Tiziana Life Sciences announces patient dosing in Phase 2 MS trial at University of Massachusetts

April 23, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces University of Massachusetts Commences Dosing Intranasal Foralumab in Phase 2 Multiple Sclerosis Trial

April 23, 2025 | globenewswire.com

Tiziana Life announces dosing at JHU, part of Phase 2 trial of foralumab

April 3, 2025 | markets.businessinsider.com

Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins

April 2, 2025 | proactiveinvestors.com

Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial

April 2, 2025 | globenewswire.com

Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS

March 25, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
By Sam Quirke | May 13, 2025
View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for Long
Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
By Nathan Reiff | April 30, 2025
View Why D-Wave's Project With Davidson Is a Game-Changer For Quantum
ExxonMobil: Production Offset Prices, Capital Return Safe in 2025
By Thomas Hughes | May 5, 2025
View ExxonMobil: Production Offset Prices, Capital Return Safe in 2025
Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast
By Jeffrey Neal Johnson | May 9, 2025
View Datadog Earnings Delight: Q1 Strength and an Upbeat Forecast
3 American Outperformers Are Lifting and Initiating Dividends
By Leo Miller | May 12, 2025
View 3 American Outperformers Are Lifting and Initiating Dividends

ABEO, DARE, TLSA, and INCR Company Descriptions

Abeona Therapeutics NASDAQ:ABEO

$6.12 -0.30 (-4.67%)

Closing price 04:00 PM Eastern

Extended Trading

$6.12 +0.00 (+0.08%)

As of 07:19 PM Eastern

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.

Daré Bioscience NASDAQ:DARE

$2.80 -0.10 (-3.45%)

Closing price 04:00 PM Eastern

Extended Trading

$2.82 +0.03 (+0.89%)

As of 07:54 PM Eastern

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

InterCure NASDAQ:INCR

$1.55 0.00 (0.00%)

Closing price 03:57 PM Eastern

Extended Trading

$1.55 0.00 (0.00%)

As of 05:05 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.

Tiziana Life Sciences NASDAQ:TLSA

$1.43 -0.15 (-9.49%)

Closing price 04:00 PM Eastern

Extended Trading

$1.46 +0.03 (+2.38%)

As of 07:34 PM Eastern

Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases. It also develops Milciclib (TZLS-201), a small molecule inhibitor of various cyclin-dependent kinases, tropomycin receptor kinases, and Src family kinases controlling cell growth and malignant progression of cancer; and anti- receptor (IL6R) mAb (TZLS-501), a fully human monoclonal antibody for the treatment of IL6-induced inflammation and to treat COVID-19 patients. Tiziana Life Sciences Ltd was incorporated in 1998 and is headquartered in London, the United Kingdom.Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time